Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes

References

• Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. Eur J Haematol. 2018;101(3):260–271.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
   PubMed Web of Science ®Google Scholar
• Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018;8(5):47.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al. Myelodysplastic Syndrome-003 Study I. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–1465.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Chokr N, Stahl M, et al. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Rev Hematol. 2018;11(9):715–726.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA. 2011;305(8):814–819.
   PubMed Web of Science ®Google Scholar
• Parikh AR, Olnes MJ, Barrett AJ. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol. 2012;49(4):304–311.
   PubMed Web of Science ®Google Scholar
• Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980–983.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematol. 2018;18(1):4.
   PubMedGoogle Scholar
• Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536–547.
   PubMed Web of Science ®Google Scholar
• Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology Am Soc Hematol Educ Program. 2016;2016(1):478–484.
   PubMed Web of Science ®Google Scholar
• Kroger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35(19):2157–2164.
   PubMed Web of Science ®Google Scholar
• Saber W, Cutler CS, Nakamura R, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122(11):1974–1982.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–3510.
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Trapianto di Midollo O. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the gruppo italiano trapianto di midollo osseo (GITMO). Blood. 2008;112(3):895–902.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22(3):538–543.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–2506. .
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247.
   PubMed Web of Science ®Google Scholar
• Nazha A, Al-Issa K, Hamilton BK, et al. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia. 2017;31(12):2848–2850.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Gangat N, Mudireddy M, et al. Mayo alliance prognostic model for myelodysplastic syndromes: integration of genetic and clinical information. Mayo Clin Proc. 2018;93(10):1363–1374.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Patnaik MM, et al. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. Am J Hematol. 2017;92(12):1311–1317.
   PubMed Web of Science ®Google Scholar
• Navarro I, Ruiz MA, Cabello A, et al. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. Leuk Res. 2006;30(8):971–977.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Cazzola M, Boultwood J, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome C. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–1395. .
   PubMed Web of Science ®Google Scholar
• Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Leukemia. 2016;30(11):2214–2220.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome C. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627. quiz 99. .
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–585. .
   PubMed Web of Science ®Google Scholar
• Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31(21):2662–2670. .
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Porta MG, Malcovati L, et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol. 2013;88(7):581–588.
   PubMed Web of Science ®Google Scholar
• Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154–1161.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Lee S, Zhu X, et al. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23(9):1417–1421.
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Ahn KW, Hu ZH, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016;34(16):1864–1871.
   PubMed Web of Science ®Google Scholar
• de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753–1762.
   PubMed Web of Science ®Google Scholar
• Scott BL Long-term follow up of BMT CTN 0901, a randomized phase III trial comparing myeloablative (MAC) to reduced intensity conditioning (RIC) prior to hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplasia (MDS) (MAvRIC trial). Abstract 11. Presented at: TCT | Transplantation & Cellular Therapy Meetings; Feb. 19-23, 2020; Orlando.
   Google Scholar
• Robin M, Porcher R, Zinke-Cerwenka W, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the chronic malignancy working party of the EBMT. Bone Marrow Transplant. 2017;52(2):209–215. .
   PubMed Web of Science ®Google Scholar
• Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116(9):2174–2179.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European leukemiaNet. Blood. 2013;122(17):2943–2964.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019 2019 Nov 25. Accessed: http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
   PubMed Web of Science ®Google Scholar
• Pulsipher MA. Reduced intensity for myelodysplastic syndrome: worth the gamble? J Clin Oncol. 2017;35(19):2106–2108.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246–4254.
   PubMed Web of Science ®Google Scholar
• Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112(9):1992–2001.
   PubMed Web of Science ®Google Scholar
• Elsawy M, Storer BE, Milano F, et al. Prognostic performance of the augmented hematopoietic cell transplantation-specific comorbidity/age index in recipients of allogeneic hematopoietic stem cell transplantation from alternative graft sources. Biol Blood Marrow Transplant. 2019;25(5):1045–1052.
   PubMed Web of Science ®Google Scholar
• Hou HA, Tsai CH, Lin CC, et al. Incorporation of mutations in five genes in the revised international prognostic scoring system can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J. 2018;8(4):39.
   PubMedGoogle Scholar
• Bernard E, Nannya Y, Yoshizato T, et al. TP53 state dictates genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Blood. 2019;134(Supplement_1):675. .
   Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32(25):2691–2698.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Galli A, Bacigalupo A, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34(30):3627–3637.
   PubMed Web of Science ®Google Scholar
• Duncavage EJ, Jacoby MA, Chang GS, et al. Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med. 2018;379(11):1028–1041.
   PubMed Web of Science ®Google Scholar
• Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist. 2011;16(Suppl S3):35–42.
   PubMedGoogle Scholar
• Buccisano F, Piccioni AL, Nobile C, et al. Grom. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study. Ann Hematol. 2016;95(7):1059–1065.
   PubMed Web of Science ®Google Scholar
• Messa E, Gioia D, Masiera E, et al. Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. Haematologica. 2019;104(1):e4–e8.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Zeidan AM. Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Leuk Lymphoma. 2018;59(9):2015–17.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140–151.
   PubMed Web of Science ®Google Scholar
• Park S, Hamel JF, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol. 2017;35(14):1591–1597.
   PubMed Web of Science ®Google Scholar
• Prebet T, Cluzeau T, Park S, et al. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget. 2017;8(47):81926–81935.
   PubMedGoogle Scholar
• Prebet T, Toma A, Cluzeau T, et al. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget. 2017;8(23):37866–37874.
   PubMedGoogle Scholar
• Jabbour EJ, Garcia-Manero G, Strati P, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS clinical research consortium. Cancer. 2015;121:876–882.
   PubMed Web of Science ®Google Scholar
• Prebet T, Thepot S, Gore SD, et al. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica. 2013;98(2):e18–9.
   PubMed Web of Science ®Google Scholar
• Nazha A, Seastone D, Radivoyevitch T, et al. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015;100(11):e434–7.
   PubMed Web of Science ®Google Scholar
• Huang TC, Ko BS, Tang JL, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by international prognostic scoring system, cytogenetic and genetic studies. Leukemia. 2008;22(3):544–550.
   PubMed Web of Science ®Google Scholar
• Bono E, McLornan D, Travaglino E, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33(10):2495–2505.
   PubMed Web of Science ®Google Scholar
• Hunt AA, Khan AB, Potter VT, et al. Hypoplastic MDS is a distinct clinico-pathological entity with somatic mutations frequent in patients with prior aplastic anaemia with favorable clinical outcome. Blood. 2014;124(21):3269.
   Web of Science ®Google Scholar
• Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37(1):15–29.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: etiology, molecular pathogenesis, and emerging concepts. Eur J Haematol. 2018;101(6):711–720.
   PubMed Web of Science ®Google Scholar
• Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6(8):e23109.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1–10.
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95(3):476–484.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Virtanen JM, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014;20(8):1248–1251.
   PubMed Web of Science ®Google Scholar
• Armand P, Sainvil MM, Kim HT, et al. Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012;87(6):569–572.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Fiaccadori V, Gandhi S, et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res. 2010;34(6):723–727.
   PubMed Web of Science ®Google Scholar
• Artz AS, Logan B, Zhu X, et al. from the Center for International B, Marrow Transplantation R. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016;101(11):1426–1433. .
   PubMed Web of Science ®Google Scholar
• Wermke M, Schmidt A, Middeke JM, et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res. 2012;18(23):6460–6468.
   PubMed Web of Science ®Google Scholar
• Wermke M, Eckoldt J, Gotze KS, et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol. 2018;5(5):e201–e10.
   PubMed Web of Science ®Google Scholar
• Trottier BJ, Burns LJ, DeFor TE, et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood. 2013;122(9):1678–1684.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Giri S, DeVeaux M, et al. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Ann Hematol. 2019;98(2):339–350.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Li J, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind Telesto study. Abstract #234. Presented at the 2018 ASH Annual Meeting, December 1, 2018; San Diego, CA.
   Google Scholar
• Alessandrino EP, Angelucci E, Cazzola M, et al. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the gruppo Italiano trapianto di midollo osseo. Am J Hematol. 2011;86:897–902.
   PubMedGoogle Scholar
• Sivgin S, Baldane S, Akyol G, et al. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. Transfus Apher Sci. 2013;49(2):295–301.
   PubMed Web of Science ®Google Scholar
• Musto P, Maurillo L, Simeon V, et al. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol. 2017;177(5):741–750.
   PubMed Web of Science ®Google Scholar
• Leitch HA, Buckstein R, Zhu N, et al. Iron overload in myelodysplastic syndromes: evidence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018;74:21–41.
   PubMed Web of Science ®Google Scholar
• Buesche G, Teoman H, Wilczak W, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2008;22(2):313–322.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Malcovati L. Myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2011;96(2):180–183.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–762.
   PubMed Web of Science ®Google Scholar
• Lambertenghi-Deliliers G, Orazi A, Luksch R, et al. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991;78(2):161–166.
   PubMed Web of Science ®Google Scholar
• Ramos F, Robledo C, Izquierdo-Garcia FM, et al. Spanish Group for Myelodysplastic S. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. Oncotarget. 2016;7(21):30492–30503. .
   PubMedGoogle Scholar
• Reda G, Riva M, Fattizzo B, et al. Bone marrow fibrosis and early hematological response as predictors of poor outcome in azacitidine treated high risk-patients with myelodysplastic syndromes or acute myeloid leukemia. Semin Hematol. 2018;55(4):202–208.
   PubMed Web of Science ®Google Scholar
• Hussein K, Stucki-Koch A, Kreipe H. Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis. Ann Hematol. 2018;97(11):2099–2106.
   PubMed Web of Science ®Google Scholar
• Duarte FB, Barbosa MC, Jesus DSTE, et al. Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low-risk myelodysplastic syndrome. Br J Haematol. 2018;181(4):547–549.
   PubMed Web of Science ®Google Scholar
• McLornan DP, Yakoub-Agha I, Robin M, et al. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659–668.
   PubMed Web of Science ®Google Scholar
• Loghavi S, Al-Ibraheemi A, Zuo Z, et al. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015;171(1):91–99.
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, van Biezen A, et al. Blood MDSSotCLWPotEGf, Marrow T. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2011;96(2):291–297.
   PubMed Web of Science ®Google Scholar
• Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2013;26(4):309–317.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Al Ali N, Barnard J, et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS clinical research consortium. Leukemia. 2017;31:1391–1397.
   PubMed Web of Science ®Google Scholar
• Smith RE, Bryant J, DeCillis A, et al. National Surgical Adjuvant B, Bowel Project E. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol. 2003;21(7):1195–1204. .
   PubMed Web of Science ®Google Scholar
• Malmgren JA, Calip GS, Pyott SM, et al. Therapy-related myelodysplastic syndrome following primary breast cancer. Leuk Res. 2016;47:178–184.
   PubMed Web of Science ®Google Scholar
• Granfeldt Ostgard LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641–3649.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Pham A, Li SM, et al. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. Haematologica. 2017;102(12):2030–2038.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Boddu PC, Bewersdorf JP, et al. The golden age for patients in their golden years: the progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Rev. 2019;100639. DOI:10.1016/j.blre.2019.100639
   PubMed Web of Science ®Google Scholar
• Garcia JS, Kim HT, Brock J, et al. 1 Dose-escalation study of adding venetoclax to a reduced intensity conditioning (RIC) regimen prior to allogeneic hematopoietic cell transplantation for patients with high risk myeloid malignancies. Blood. 2019;134(Supplement_1):258.
   Google Scholar
• Sallman DA, DeZern AE, Garcia-Manero G, et al. Phase 2 Results of APR_246 and Azacitidine (AZA) in Patients with TP53-mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood. 2019;134 (Supplement_1):676.
   Google Scholar
• Cluzeau T, Sebert M, Rahmé R, et al. APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). a phase 2 study by the groupe francophone des myélodysplasies (GFM). Blood. 2019;134(Supplement_1):677.
   Web of Science ®Google Scholar